zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
Published 4 years ago • 112 plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
1:44
comparison of zuma-1 and scholar-1 outcomes
-
2:09
zuma series update: zuma-1 and zuma-2
-
3:32
zuma-1: updated data and future prospects
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
1:15
primary overall survival analysis of the zuma-7 trial
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl
-
1:41
zuma-1: 3-year follow-up on axi-cel in lbcl patients
-
24:03
a comparison of optical and impedance platelet counts on the yumizen platform
-
49:01
ukmla akt haematology - presentations and management | multiple choice questions
-
26:31
survival analysis overview
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
4:44
zuma-7 subgroup analysis: axi-cel vs soc in elderly patients with r/r lbcl
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
2:00
long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
-
2:06
zuma-12: axi-cel as first-line therapy in high-risk large b-cell lymphoma
-
2:52
zuma-24 preliminary analysis of axi-cel in the outpatient setting in patients with r/r lbcl
-
1:11
zuma-11 study overview: axi-cel plus utomilumab in r/r dlbcl
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
2:48
results from a subgroup analysis of zuma-3 and the efficacy of brexu-cel in r/r b-all
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
2:57
linker-mm1: promising safety and efficacy of linvoseltamab in r/r multiple myeloma
-
6:28
outcomes following first-line therapy in routine clinical practice in alcl